Sorry, Tesaro. AZ's Lynparza won a broader-than-expected approval in ovarian cancer, putting it on even footing with Tesaro’s recent launch, Zejula.…
Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.
Purdue, which has been fending off lawsuits over pain drug OxyContin in the U.S., may have to face off against Canada’s federal government.
Opioid makers face a task that’s partly old, partly new. Besides training docs on their meds' risks, they'd have to include info on rival therapies.
Transparency hasn't made much of a difference when it comes to drug and device makers' payments to doctors, which amounted to $2.6 billion last year.
Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.
With biologics dominating its pipeline, Sanofi will spend as much as $2 billion on its biologics manufacturing network over the next several years.
Novo Nordisk just took another step toward a potential kick-start for its newest basal insulin, Tresiba.
In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.
California lawmakers are weighing a bill that would cut off most drugmaker payments to physicians, including speaking fees for that staple of pharma marketing…